American Vietnamese Biotech (HSTC:AMV) Equity-to-Asset: 0.00 (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is American Vietnamese Biotech Equity-to-Asset?

American Vietnamese Biotech HSTC:AMV Equity-to-Asset is 0.00 as of . 20.

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. American Vietnamese Biotech's Total Stockholders Equity for the quarter that ended in . 20 was ₫0.00 Mil. American Vietnamese Biotech's Total Assets for the quarter that ended in . 20 was ₫0.00 Mil.

The historical rank and industry rank for American Vietnamese Biotech's Equity-to-Asset or its related term are showing as below:

HSTC:AMV's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.68
* Ranked among companies with meaningful Equity-to-Asset only.

American Vietnamese Biotech  (HSTC:AMV) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

American Vietnamese Biotech Equity-to-Asset Related Terms

American Vietnamese Biotech Equity-to-Asset Historical Data

* Premium members only.

The historical data trend for American Vietnamese Biotech's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

American Vietnamese Biotech Equity-to-Asset Chart

American Vietnamese Biotech Annual Data
Trend
Equity-to-Asset

American Vietnamese Biotech Quarterly Data
Equity-to-Asset

HSTC:AMV vs HSTC, STLT, CTBO: Equity-to-Asset Comparison

For the Biotechnology subindustry, American Vietnamese Biotech's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

American Vietnamese Biotech Equity-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, American Vietnamese Biotech's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where American Vietnamese Biotech's Equity-to-Asset falls into.


American Vietnamese Biotech Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

American Vietnamese Biotech's Equity to Asset Ratio for the fiscal year that ended in . 20 is calculated as

Equity to Asset (A: . 20 )=Total Stockholders Equity/Total Assets
=/
=

American Vietnamese Biotech's Equity to Asset Ratio for the quarter that ended in . 20 is calculated as

Equity to Asset (Q: . 20 )=Total Stockholders Equity/Total Assets
=/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Equity-to-Asset →
What does a Equity-to-Asset of 0.00 mean?
American Vietnamese Biotech (HSTC:AMV) has a Equity-to-Asset of 0.00 as of . 20. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on American Vietnamese Biotech and its competitors.
Is American Vietnamese Biotech's Equity-to-Asset too high?
American Vietnamese Biotech's current Equity-to-Asset is 0.00.
How does American Vietnamese Biotech's Equity-to-Asset compare to HSTC and STLT?
American Vietnamese Biotech's Equity-to-Asset of 0.00 can be compared against companies in the Biotechnology industry. The industry median Equity-to-Asset is 0.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on American Vietnamese Biotech and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. American Vietnamese Biotech's current Equity-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is American Vietnamese Biotech stock overvalued right now?
American Vietnamese Biotech (HSTC:AMV) has a current Equity-to-Asset of 0.00. The current Equity-to-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For American Vietnamese Biotech (HSTC:AMV), the current Equity-to-Asset is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

American Vietnamese Biotech Business Description

Address No. 85 Hoang Van Thai, 4th Floor, Phu Ma Duong Building, Tan Phu Ward, District 7, Ho Chi Minh, VNM
American Vietnamese Biotech Incorporation is engaged in trading in pharmaceuticals, purchasing and selling medical equipment, medical testing instruments, and chemicals; producing and trading vaccines and medical biological products.